
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc is positioned favorably in the ADHD medication market, which has seen consistent growth of approximately 8% annually, culminating in sales of around $18 billion in 2020. The company is focusing on the development of its proprietary ADHD medications, CTx-1301 and CTx-1302, with regulatory approval anticipated in mid-2026, potentially serving as a strong catalyst for stock performance. Furthermore, the current valuation of Cingulate stock appears attractive when assessed through a net present value analysis, indicating significant upside potential relative to the existing share price despite inherent risks.
Bears say
Cingulate Inc reported a net loss of $7.3 million, equating to an earnings per share (EPS) of $(1.35), which significantly exceeded both the company's estimates and consensus expectations for the quarter. The company also recorded a previous net loss of $6.5 million with an EPS of $(0.93), which again fell short of its and the market's projections. Key risks affecting the outlook include liquidity challenges, the potential inability of product candidates to prove safety and efficacy, regulatory approval hurdles, commercialization difficulties, reimbursement issues, and broader competitive and economic pressures impacting investor sentiment towards biotech stocks.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares